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Abstract
Ceramide synthases (CerS) are integral membrane proteins of the endoplasmic reticulum. Six mammalian CerS have been described, with each utilizing fatty acyl CoAs of relatively deined chain lengths for N‑acylation of the sphingoid long chain base. In this chapter, 
we review the main functional features of the CerS proteins, discuss their fatty acid speciicity, 
kinetics, tissue distribution and mode of inhibition, as well as possible posttranslational modiica‑
tions. We then address the reason that mammals contain six distinct CerS, whereas most other 
enzymes in the sphingolipid biosynthetic pathway only occur in one or two isoforms. Finally, we 
discuss the putative roles of CerS and the ceramide derived from the CerS, in signaling pathways 
and in development of disease.
Introduction
Ceramide (Cer) is an important bioactive lipid that has been implicated in a variety of cell 
biological processes ranging from regulation of cell growth to cell death and senescence.1‑3 he 
biochemical pathways by which Cer is generated are highly conserved between mammals and 
yeast.4 Cer is composed of a long chain base (LCB), sphingosine (or sphinganine in the case of 
dihydroceramide (Fig. 1A)), which is acylated at the free amine nitrogen to form an amide bond. 
he N‑acylation reaction is catalyzed by ceramide synthases (CerS).
he irst molecular characterization of genes involved in de novo Cer synthesis was made about 
6‑7 years ago with the observation that two genes in yeast, Lag1p and Lac1p, were required for 
C26‑Cer production5,6 (C26 indicates an acyl chain of 26 carbon atoms), the main Cer species 
found in yeast. Around this time, an earlier version of this book was published.7 Strikingly, in the 
earlier version there was no discussion of the molecular identiication of CerS; thus, the current 
chapter serves not only to update the earlier book, but also demonstrates the remarkable progress 
made in the study of CerS over the past 5‑6 years.
Ater the discovery of Lag1p and Lac1p, database searches over the next couple of years8,9 re‑
vealed six mammalian homologs, which were initially named Lass (Longevity Assurance) genes, 
but were recently renamed CerS (Ceramide Synthase)10 due to the assignment of their function as 
genuine ceramide synthases.11 Figure 1B shows the alignment of the sequences of the human CerS 
family compared to the two yeast proteins. Phylogenetically, CerS1 is more closely related to yeast 
Lag1p and Lac1p than to the other mammalian homologs (Fig. 1C).10,12 Moreover, all mammalian 
CerS, except CerS1, contain a Hox‑like domain;13 however, this Hox‑like domain is unlikely to 
act as a transcription factor since the irst 15 amino acid residues of the Hox domain are missing 
as are key residues involved in DNA binding. In addition, most of the Hox‑like domain can be 
deleted without afecting catalytic activity.13 hus, the function of the Hox‑like domain in (Hox)
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2 Sphingolipids as Signaling and Regulatory Molecules
Figure 1. An overview of CerS biochemistry. A) Structures of CerS substrates and prod-
ucts. B) Alignments (performed using ClustalW2 (http://www.ebi.ac.uk/Tools/clustalw2/
index.html)). C) Phylogenetic tree comparing human and yeast CerS.
A
B
C
CerS (i.e., those CerS which contain a Hox‑like domain) is currently unknown. In yeast, 
an additional subunit, Lip1, is required for ceramide synthesis,14 but mammalian CerS do 
not appear to require any accessory proteins for activity.11
he main functional region of the CerS is the TLC (Tram‑Lag‑CLN8) domain,9,10 
a region of ~200 residues also found in other proteins.9 his deinition is based on two 
additional proteins, Tram1 and CLN8; Tram1 was found in a search for homologs of 
Lag1 in humans. he CerS active site is located in the TLC domain; however, other 
members of the TLC domain‑containing family do not appear to have CerS activity 
although they may modulate CerS activity.15
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3Ceramide Synthesis and Cell Signaling
Since their discovery, great interest has been shown in characterizing the CerS, with a view to 
understanding their biochemistry and their biology. It is these aspects that we will now review.
Fatty Acid Speciicity, Kinetics and Tissue Distribution
Each mammalian CerS utilizes fatty acyl CoAs of relatively deined chain lengths for Cer 
synthesis (Table 1), using either sphinganine (derived from the biosynthetic pathway) or sphin‑
gosine (derived from SL recycling) as the LCB. hus, CerS1 uses mostly C18‑CoA,16 CerS4 uses 
C18‑ and C20‑CoAs,17 CerS5 and CerS6 use mostly C16‑CoA12,17 and CerS3 uses very long chain 
acyl CoAs (C26 and higher).18 CerS2 can utilize a wider range of fatty acyl CoAs, from C20 to 
C26, but does not use C16‑ or C18‑CoAs.19 he CerS produce 2‑hydroxy (α‑hydroxy) Cer with 
a chain length similar to that of the respective nonhydroxy‑Cer.20
A recent study examined the kinetics of Cer formation. Reactions proceeded according to 
classical Michaelis‑Menten kinetics21 and the Km values of all CerS towards sphinganine were 
in the low µM range (Table 1). It should be noted that the Km values reported in this study 
were considerably lower than some reported earlier, in which values as high as 300 µM were 
obtained (reviewed in ref. 22). his may be due to the use of detergents in some of these earlier 
assays, rather than the detergent‑free method described in reference 21. Interestingly, CerS4, 
which can use either C18‑CoA or C20‑CoA,17 has an identical Km value towards sphinganine 
irrespective of the acyl CoA chain length. his strongly supports the notion that the main 
biochemical diference between the CerS proteins is in their use of acyl CoAs and that the 
LCB binding site may be similar between CerS, although this cannot exclude the possibility 
that diferent CerS have diferent ainities towards diferent LCBs, as appears to be the case 
with CerS5.17
he CerS are diferentially distributed in various tissues, such that subsets of Cer difering in 
acyl chain length could be made in speciic tissues, presumably to meet the diferent physiological 
needs of each tissue. Analysis of levels of CerS mRNA in 14 mouse tissues19 demonstrated that 
CerS2 was the most ubiquitously expressed, with the highest expression in kidney and liver (30‑40 
molecules RNA/ng total RNA) (Table 1). CerS5 and CerS6 are also expressed in most tissues, but 
Table 1. Biochemical and physiological features of CerS
CerS
Acyl CoA 
Specificitya,b,c Tissue Distributiond
mRNA Level  
in Predominant 
Tissued 
(Molecules/ 
ng RNA)
Km Towards 
Sphinganinee 
(µM)
Mitochondrial 
Localizationf
1 C18, C18:1 Brain/skeletal 
muscles
3.3 ± 0.25 2.5 ± 0.7 Yes
2 C20, C22, C24, 
C24:1, C26
Kidney/liver 25-35 4.8 ± 0.4 Yes
3 C26 and above Testes 22 ± 1.3 1.7 ± 0.4 Not measured
4 C18, C20 Heart/leucocytes/
liver/skin
6-8 1.8 ± 0.4 No
5 C14, C16, C18, 
C18:1
All tissues—high in 
lung and epitheliag
0.15-1.7 1.8 ± 0.4 No
6 C14, C16, C18 Intestine/kidney 2.5-3 2.0 ± 0.6 Yes
aVenkataraman et al, 2002; Riebeling et al, 2003; Lahiri et al, 2005; Laviad et al, 2008; bMizutani et al, 
2005; 2006; cSpassieva et al, 2006; dRiebeling et al, 2003; Laviad et al, 2008; eLahiri et al, 2007; fYu 
et al, 2007; gXu et al, 2005.
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4 Sphingolipids as Signaling and Regulatory Molecules
the expression levels (~1‑3 molecules RNA/ng total RNA) are much lower than those of CerS2; 
in another study, CerS5 was found to be highly expressed in mouse lung epithelial cells.23 CerS4 
is expressed in most tissues with the skin, leukocytes, heart and liver showing highest expression. 
CerS3 is exclusively expressed in testes18,19 and skin,19 speciically keratinocytes,20 whereas CerS1 
is highly expressed in brain and skeletal muscles.
To determine if there is a correlation between CerS mRNA levels and Cer acyl chain lengths 
in diferent tissues, the distribution of Cer subspecies was compared to those of the relative ex‑
pression levels of CerS mRNA.19 he two tissues with the highest CerS2 mRNA levels, kidney 
and liver, also had the highest proportions of C22 to C24‑Cer. Kidney also has high proportions 
of C22‑24 acyl chains in sphingomyelin (SM) and hexosylceramides (HexCer) as does liver, al‑
though the N‑acyl chain composition of HexCer difers from that of Cer and SM. For the other 
three tissues examined (brain, testis and skeletal muscle), CerS2 mRNA was less prevalent than 
the mRNAs of the other CerS and the proportions of C22‑, C24‑ and C24:1‑Cer and ‑SMs are 
correspondingly lower. Interestingly, for two of these tissues (brain and skeletal muscle), HexCer 
contains surprisingly high proportions of C22‑24‑Cer, suggesting that there are factors other than 
the relative amounts of the CerS mRNA that afect the Cer subspecies distribution, particularly 
in downstream complex SLs and glycosphingolipids.
Most studies, at least those using immunofluorescence to examine the localization of 
ectopically‑expressed proteins, suggest that CerS are located exclusively to the endoplasmic 
reticulum with no colocalization with mitochondrial markers;16,17,19 earlier biochemical studies 
demonstrated that the CerS are found on the cytoplasmic lealet of the ER.24,25 Nevertheless, there 
is some evidence, based on biochemical isolation of sub‑cellular fractions followed by Western 
blotting, that CerS can be detected in mitochondria and/or mitochondrial‑associated ER mem‑
branes26,27 (Table 1). Determination of the precise intracellular localization of the CerS awaits the 
generation of high quality speciic antibodies.
Inhibitors
A number of speciic inhibitors of CerS have been described, the most notable of which 
is Fumonisin, a mycotoxin derived from Fusarium. Another fungal‑derived inhibitor is 
Australifungin. A third compound, the immunomodulator, FTY720, was recently shown to 
inhibit CerS activity.
Fumonisins
Fumonisin (FB) was irst shown to inhibit Cer synthesis in 1991,28 before the molecular identi‑
ication of the CerS. Fumonisins are isolated from Fusarium moulds (which occur mainly in maize) 
and they bear considerable structural similarity to the LCB backbone of SLs. Two derivatives, FB1 
and FB2, are potent inhibitors of CerS; FB1 inhibits CerS activity in rat liver microsomes and in 
isolated hepatocytes with an IC50 value of ~0.1 µM.28 Further early studies demonstrated that in‑
hibition occurs via competitive‑like inhibition towards both sphinganine and C18‑CoA29 and that 
FB1 and FB2 block the proliferation of LLC‑PK1 cells at concentrations between 10 and 35 µM; 
concentrations over 35 µM were cytotoxic.30 FB1 is a speciic inhibitor of the CerS, as no inhibitory 
efects were observed on the activities of other enzymes in the SL biosynthetic pathway.31 In addition, 
FB1 was shown to block Cer synthesis in cultured hippocampal neurons, which led to signiicant 
changes in the rates of neuronal growth.32,33
Since these early studies, FB1 has been extensively used as an inhibitor of the de novo SL 
biosynthetic pathway in cell cultures as well as in animals and is routinely used to distinguish 
the efects of Cer generated via the action of sphingomyelinases compared to Cer generated de 
novo. However, since FB1 inhibits not only Cer synthesis, but also the synthesis of all subsequent 
down‑stream SLs (i.e., SM and glycosphingolipids), care must be taken in the interpretation of 
results obtained ater relatively long times of inhibition with FB1 (i.e., more than one hour). 
Moreover, upon over‑expression of CerS activity in some cultured cells, FB1 elevates Cer levels.8,17 
he reason for this is unclear and to date there is no evidence that Cer is elevated by treatment 
with FB1 in cells that do not overexpress CerS.
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5Ceramide Synthesis and Cell Signaling
Australifungin
Australifungin is a broad‑range antifungal agent that acts against human pathogenic fungi at 
ranges from 0.015 to 1.0 µg/ml. Australifungin speciically inhibits SL synthesis by blocking CerS 
activity.34 In crude membranes derived from yeast, the inhibitory concentration of Australifungin 
was 10 µM.35 However, Australifungin is much less widely used as a CerS inhibitor than FB1.
FTY720
FTY720, a sphingosine analog, is in clinical trials as an immunomodulator. he biological 
efects of FTY720 are believed to occur mainly ater its metabolism to FTY720 phosphate 
(FTY720‑P). However, until recently, it was not known if FTY720 itself could interact with 
and modulate the activity of other enzymes of SL metabolism. Recently, we demonstrated that 
FTY720 inhibits CerS activity in vitro by noncompetitive inhibition towards acyl CoAs and 
uncompetitive inhibition towards sphinganine; the EC50 of inhibition varied from ~12‑66 µM 
depending on the CerS and on the acyl chain length.36 In cultured cells, FTY720 had a more 
complex efect, with Cer synthesis inhibited at high (500 nM to 5 µM) but not low (<200 
nM) sphinganine concentrations, consistent with FTY720 acting as an uncompetitive inhibi‑
tor towards sphinganine. Finally and unexpectedly, elevated levels of Cer, SM and HexCers 
were observed ater short times of incubation with FTY720. hese data suggest that some of 
the efects of FTY720 observed in vivo might need to be re‑evaluated in light of its ability to 
modulate CerS activity.36
Posttranslational Modiications
Indirect evidence from over a decade ago, based on rapid changes in CerS activity ater vari‑
ous stimuli, suggested that CerS are likely to be modiied posttranslationally.37,38 Accumulating 
evidence supports a role for phosphorylation in the posttranslational modiication of CerS. 
Activation of protein kinase C (PKC) increases de novo Cer synthesis,39 which was attributed 
to up‑regulation of CerS5 activity.40 Deletion of the α’‑catalytic subunit of casein kinase II in 
yeast reduced levels of Cer produced in vitro35 and yeast lacking TOR (Target of Rapamycin) 
could not synthesize Cer. Ypk2, a kinase activated by TOR2, induces CerS activity and this step 
is antagonized by the Ca2+/calmodulin‑dependent phosphatase, calcineurin.41 Calcineurin has 
also been shown to negatively regulate the formation of complex SLs42,43 and the overexpression 
of calcineurin B subunit enhanced the oncogenic potential of HEK 293T cells.44 hus, indirect 
evidence suggests that CerS are modulated by phosphorylation, a notion supported by data from 
high performance mass spectrometry suggesting that mouse liver CerS2 and CerS5 are phos‑
phorylated.45 Moreover, CerS1 turnover ater various drug treatments46 appears to be regulated 
by the opposing actions of p38 MAP kinase and protein kinase C (PKC); p38 MAP kinase is a 
positive regulator of turnover, while PKC is a negative regulator of turnover. Pulse‑chase labeling 
experiments demonstrated that CerS1 is phosphorylated in vivo and activation of PKC increases 
the phosphorylation of the protein.47 he possible role of phosphorylation in regulating CerS 
activity is illustrated in Figure 2.
Membrane Topology
Early proteolytic digestion experiments implied that the active site of CerS faces the cytosol.25 
More recently, Igarashi and colleagues suggested that CerS2, 5 and 6 have ive transmembrane do‑
mains; moreover, the N‑terminus of these CerS is inside the lumen of the endoplasmic reticulum 
and the C‑terminus, at least of CerS6, is in the cytosol.12 However, another study suggested that the 
yeast CerS, Lag1p and Lac1p, have eight putative trans‑membrane domains, with both the N‑ and 
C‑termini facing the cytosol;48 the conserved Lag motif, which contains the potential active site, was 
suggested to be embedded in the membrane.48 We have tried to resolve this issue using the PHD 
predicted protein server,49 which suggests that mammalian CerS have six putative trans‑membrane 
domains with both N‑ and C‑termini facing the cytosol (Fig. 3). Veriication of the trans‑membrane 
topology of the CerS awaits more detailed structural analyses and ultimately, resolution of their 
crystal structures.
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6 Sphingolipids as Signaling and Regulatory Molecules
Figure 2. A putative role for CerS in regulating cell death. There have been suggestions that 
CerS can be phosphorylated (see text). Phosphorylation could occur via PKC (protein kinase 
C), CK II (casein kinase 2) or Ypk2 (or its mammalian orthologs, SGK and/or Akt/PKB) resulting 
in activated CerS and generation of pro-apoptotic Cer. Calcineurin could act in the opposite 
manner, by dephosphorylating CerS. The phosphates shown on the CerS are for illustration 
purposes only since there are currently no reports on CerS phosphorylation sites.
Figure 3. Predicted membrane topology of CerS. The prediction was performed using the PHD 
predict protein server (http://cubic.bioc.columbia.edu), which suggested six membrane spanning 
domains with both the N- and C-termini on the cytosolic leaflet (of the endoplasmic reticulum). 
The Hox-like domain (found in CerS2-6), shown as a dashed line, is located in the 1st lumenal loop. 
The TLC domain, shown in dark gray, begins at the end of the 1st lumenal loop and continues to 
the end of the 6th transmembrane domain. The Lag1p motif (which is part of the TLC domain) is 
shown in light gray and begins in the middle of the 2nd lumenal loop and continues through to 
the 2nd cytosolic loop. The two conserved histidine residues, which are proposed to be active 
site residues, are also shown; the enlargement shows the sequence of human CerS5.
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7Ceramide Synthesis and Cell Signaling
Why Are here So Many Mammalian CerS?
he key question related to the physiology of CerS is why there are six distinct enzymes that es‑
sentially carry out the same reaction, namely N‑acylation of the LCB, albeit with strict acyl CoA chain 
length speciicity. A relatively straightforward answer is that ceramides containing speciic fatty acids 
play more vital roles in cell physiology than once thought,10 though what these roles are have not been 
fully delineated. It is known that ceramides with diferent acyl chain lengths have distinct biophysical 
properties50,51 and the ceramides could themselves inluence the biophysical properties of the membranes 
in which they are found, by for instance, diferentially interacting with other membrane components. 
Evidence is also accumulating that ceramides with speciic acyl chain lengths are generated in diferent 
signaling pathways and that these ceramides can diferentially interact with downstream components 
in such pathways.10,52 Furthermore, the multiple levels of regulation of CerS expression17,19,23 and activ‑
ity37‑45 support a vital role for the acyl chain length of ceramide in key events of cell physiology.
Although an integrated picture of how the CerS function together is currently lacking, considerable 
progress has been made in understanding the roles of individual CerS. CerS1, the irst mammalian CerS 
to be described,16 speciically synthesizes C18‑Cer and is mainly expressed in the brain and in skeletal 
muscle and is almost undetectable in other tissues12,19 (Table 1). CerS1 appears to be involved in cancer 
regulation and in modulating drug sensitivity. Overexpression of CerS1 inhibited the growth of human 
head and neck squamous cell carcinoma cells (HNSCC) and also increased the chemotherapy‑induced 
apoptosis of these cells.53,54 Moreover, there was a correlation between attenuated C18‑Cer levels and 
the state of clinical disease, suggesting that C18‑Cer is an important player in the regulation of HNSCC 
growth and/or pathogenesis.55 CerS1 also has a unique role in regulating sensitivity to chemotherapeutic 
drugs;46,56 CerS1 expression led to an increased sensitivity to cisplatin, which is widely used to treat a 
variety of solid tumors. In response to cisplatin, CerS1 expression increased the activation of the p38 
mitogen‑activated protein (MAP) kinase and concomitantly CerS1 was translocated from the ER to 
the Golgi apparatus.46 his data suggests a potential role for CerS1 as a target for improving the eicacy 
of cisplatin therapy. In summary, CerS1 is regulated by mechanisms that involve PKC, ubiquitination 
and ER‑to‑Golgi translocation leading to its eventual proteasomal degradation.47
CerS2, which synthesizes C20‑C26‑Cer (Table 1) is the most ubiquitously expressed of all the 
CerS and has the broadest tissue distribution.17,19 In a study on the expression of CerS in the brain, 
CerS2 was found to have the highest expression of all CerS in oligodendrocytes and Schwann cells 
and its up‑regulation during myelination suggests it is responsible for the synthesis of the majority of 
SLs in myelin.57 CerS2 is also regulated by a unique mechanism, namely via sphingosine 1‑phosphate 
(S1P). S1P, but not lyso‑phosphatidic acid36 interacts with and inhibits CerS2 via two residues that are 
part of an S1P receptor‑like motif, which is found only in CerS2.19 he opposing functions that Cer 
and S1P play in signaling pathways suggests that this mode of regulation might be of signiicance in 
cell physiology and signaling. CerS2 also displays genomic features characteristic of a ‘housekeeping’ 
gene, although no other CerS genes display these characteristics.19
CerS3 is expressed at high levels in the skin,17 which contains very long acyl chain ceramides that 
are involved in maintaining the water permeability barrier function58 and in the testes, but is almost 
undetectable in other tissues.12,19 CerS3 has been postulated to be involved in sperm formation and 
androgen production;18 indeed, levels of germinal SLs containing very long acyl chains (synthesized 
by CerS3) increase during postnatal testicular maturation and are important for completion of 
spermatogenesis.59
CerS4, which uses C18‑ and C20‑CoAs17 is expressed mainly in skin, leukocytes, heart and liver.19 
CerS5, which synthesizes C16‑Cer, is expressed in most tissues.12,19 C16‑Cer is the most abundant 
short‑chain Cer in ibroblasts, endothelial cells and cells of the immune system12,60 and has been 
shown to be of particular importance in apoptosis.52,61,62 CerS6 is also expressed in most tissues12,19 
and produces short acyl chain ceramides (Table 1). However, little is known about the roles of CerS4, 
5 and 6 in speciic events in cell physiology.
One interesting diference between CerS1 and CerS4 and 5 emerged from a study looking 
at the role of each of these CerS in mediating drug sensitivity. CerS1 expression rendered cells 
more sensitive to cisplatin, carboplatin, doxorubicin and vincristine, but in contrast, expression of 
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8 Sphingolipids as Signaling and Regulatory Molecules
CerS4 did not have any efect on the cellular sensitivity to any of the agents tested, while CerS5 
expression increased the sensitivity only to doxorubicin and vincristine, but not to cisplatin and 
carboplatin.46 hese results strongly support the idea that the CerS genes are not equivalent in 
function. Similarly in yeast, the response to stress can vary from one isoform to another. Lac1p, but 
not Lag1p, is regulated by the pleiotropic drug resistance (Pdr) regulatory pathway, with Lac1p 
expression ~3 times higher than that of Lag1p.63
As summarized in this section, evidence is currently emerging that diferent CerS play diferent 
roles in mediating speciic biochemical events and thus speciic roles in cell physiology and it is 
to be hoped that their precise functions will have been clariied by the time of publication of the 
next edition of this book.
Roles of CerS in Signal Transduction and Disease
While study of the roles of individual CerS and their modes of regulation is currently in its in‑
fancy, much more is known about the roles of Cer and in particular about the roles of Cer containing 
speciic acyl chain lengths. Much of this data has emerged from study of the generation of Cer from 
SM hydrolysis (via both neutral‑ and acid‑sphingomyelinase), a research area that is somewhat more 
advanced than study of the generation of ceramides via the biosynthetic pathway.64‑66 he cross‑talk 
between the generation of these two pathways is not very well understood; likewise, the coordinate 
regulation between CerS and other enzymes in the biosynthetic pathway (i.e., serine palmitoyl 
transferase, glucosylceramide synthase etc), needs to be further studied.
However, a number of studies have shown that Cer generated via CerS can inluence cell fate, with 
up‑regulation of CerS activity causing apoptosis and down‑regulation inducing tumor formation. For 
instance, arsenic trioxide induces the production of cytotoxic levels of Cer by up‑regulating de novo 
synthesis,67 Cer production is stimulated in hypoxia/reoxygenation in NT‑2 neuronal precursor cells 
by the concerted actions of acid sphingomyelinase and CerS5,68 Cer levels are increased via the de novo 
pathway following p53 up‑regulation in leukemia and colon cancer cells and CerS5 transcriptional 
up‑regulation increases C16‑Cer levels, ultimately causing cell death.69 A variety of stress stimuli are 
known to increase Cer levels and some of these act via CerS.70 A list of agents that induce stress is 
given in Table 2, which also summarizes the putative role of CerS in these processes.
Table 2. Some stress stimuli reported to cause ceramide elevation and apoptosis. For 
a number of these stimuli, ceramide synthesis via activation of CerS has been 
implicated, as indicated.
Stressor CerS Activation Reference
UVBa radiation Yes 87
Heat Yes 88-90
Etoposide No 91
Hypoxia/reoxygenation Yes 68, 92
Ischemia/reperfusion Yes 27, 93
TNFαb Yes 94
INFγc No available data
IL-1βd No 95
Gemcitabine/doxorubicin Yes 54
Daunorubicin Yes 96
4-HPRe Yes 15
aUltraviolet B; bTumor necrosis factor α; cInterferon γ; dInterleukin-1 β; e4-(N-hydroxyphenyl)
retinamide.
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9Ceramide Synthesis and Cell Signaling
De novo Cer synthesis has also been implicated in a number of diseases,71 such as diabetes,72 
cystic ibrosis (CF)73,74 and chronic obstructive pulmonary disease (COPD). In the case of the 
latter disease, which is characterized by alveolar cell apoptosis, Cer up‑regulation via the de novo 
pathway was shown to be directly involved, since inhibition of de novo synthesis by FB1 and 
myriocin prevented disease onset.75,76 Cer is also involved in several liver conditions77 such as 
hepatic ischemia/reperfusion,78 steatohepatitis79 and Wilson disease.80 Cer may also play a role in 
Alzheimer’s disease,77 with long acyl chain Cer enriched in regions of the brain which are vulnerable 
to Alzheimer’s disease81 with concurrent elevation of CerS2 and CerS4 gene expression.82 Cer is 
involved in neuronal death83 and white matter dysfunction84,85 and increased Cer levels were sug‑
gested to be involved in cerebral ischemia and stroke.77,86 he relationship between Cer generated 
via de novo synthesis and that generated via sphingomyelinase action is an area of active study in 
each of these diseases and thus the role of regulation of CerS activity remains to be established.
Conclusion
In this chapter, we have summarized the remarkable progress made in study of the CerS genes 
and proteins since their identiication in the early 2000s. Much still remains to be understood, 
not least whether these genes are coordinately regulated, whether the CerS proteins somehow 
interact with each other (or with other proteins) and thus modulate their activity and inally, the 
precise roles of the diferent Cer species made by each CerS in the various tissues where they are 
made. he discovery of the CerS has added a new dimension to SL research and the coming years 
are sure to yield many more unexpected indings.
References
 1. Hannun YA, Obeid LM, Wolf RA. he novel second messenger ceramide: identiication, mechanism of 
action and cellular activity. Adv Lipid Res 1993; 25:43‑64.
 2. Hannun YA. Functions of ceramide in coordinating cellular responses to stress. Science 1996; 
274:1855‑1859.
 3. Futerman AH, Hannun YA. he complex life of simple sphingolipids. EMBO Rep 2004; 5:777‑782.
 4. Futerman AH, Riezman H. The ins and outs of sphingolipid synthesis. Trends Cell Biol 2005; 
15:312‑318.
 5. Guillas I, Kirchman PA, Chuard R et al. C26‑CoA‑dependent ceramide synthesis of Saccharomyces cer‑
evisiae is operated by Lag1p and Lac1p. Embo J 2001; 20:2655‑2665.
 6. Schorling S, Vallee B, Barz WP et al. Lag1p and Lac1p are essential for the Acyl‑CoA‑dependent ceramide 
synthase reaction in Saccharomyces cerevisae. Mol Biol Cell 2001; 12:3417‑3427.
 7. Futerman AH, editor. Ceramide Signaling: Kluwer Academic/Plenum Publishers 2002.
 8. Venkataraman K, Futerman A. Do longevity assurance genes containing Hox domains regulate cell devel‑
opment via ceramide synthesis? FEBS Lett 2002; 528:3‑4.
 9. Winter E, Ponting CP. TRAM, LAG1 and CLN8: members of a novel family of lipid‑sensing domains? 
Trends Biochem Sci 2002; 27:381‑383.
 10. Pewzner‑Jung Y, Ben‑Dor S, Futerman AH. When do Lasses (longevity assurance genes) become 
CerS (ceramide synthases)?: Insights into the regulation of ceramide synthesis. J Biol Chem 2006; 
281:25001‑25005.
 11. Lahiri S, Futerman AH. LASS5 is a bona ide dihydroceramide synthase that selectively utilizes palmi‑
toyl‑CoA as acyl donor. J Biol Chem 2005; 280:33735‑33738.
 12. Mizutani Y, Kihara A, Igarashi Y. Mammalian Lass6 and its related family members regulate synthesis of 
speciic ceramides. Biochem J 2005; 390:263‑271.
 13. Mesika A, Ben‑Dor S, Laviad EL et al. A new functional motif in Hox domain‑containing ceramide 
synthases: identiication of a novel region lanking the Hox and TLC domains essential for activity. J Biol 
Chem 2007; 282:27366‑27373.
 14. Vallee B, Riezman H. Lip1p: a novel subunit of acyl‑CoA ceramide synthase. Embo J 2005; 
24:730‑741.
 15. Schulz A, Mousallem T, Venkataramani M et al. he CLN9 protein, a regulator of dihydroceramide 
synthase. J Biol Chem 2006; 281:2784‑2794.
 16. Venkataraman K, Riebeling C, Bodennec J et al. Upstream of growth and diferentiation factor 1 (uog1), 
a mammalian homolog of the yeast longevity assurance gene 1 (LAG1), regulates N‑stearoyl‑sphinganine 
(C18‑(dihydro)ceramide) synthesis in a fumonisin B1‑independent manner in mammalian cells. J Biol 
Chem 2002; 277:35642‑35649.
©
20
09
 C
op
yr
ig
ht
 L
an
de
s B
io
sc
ie
nc
e.
 N
ot
 fo
r 
D
is
tr
ib
ut
io
n
10 Sphingolipids as Signaling and Regulatory Molecules
 17. Riebeling C, Allegood JC, Wang E et al. Two mammalian longevity assurance gene (LAG1) family mem‑
bers, trh1 and trh4, regulate dihydroceramide synthesis using diferent fatty acyl‑CoA donors. J Biol Chem 
2003; 278:43452‑43459.
 18. Mizutani Y, Kihara A, Igarashi Y. LASS3 (longevity assurance homologue 3) is a mainly testis‑speciic 
(dihydro)ceramide synthase with relatively broad substrate speciicity. Biochem J 2006; 398:531‑538.
 19. Laviad EL, Albee L, Pankova‑Kholmyansky I et al. Characterization of ceramide synthase 2: tissue distribu‑
tion, substrate speciicity and inhibition by sphingosine 1‑phosphate. J Biol Chem 2008; 283:5677‑5684.
 20. Mizutani Y, Kihara A, Chiba H et al. 2‑Hydroxy‑ceramide synthesis by ceramide synthase family: enzymatic 
basis for the preference of FA chain length. J Lipid Res 2008; 49:2356‑2364.
 21. Lahiri S, Lee H, Mesicek J et al. Kinetic characterization of mammalian ceramide synthases: determination 
of K(m) values towards sphinganine. FEBS Lett 2007; 581:5289‑5294.
 22. Wang E, Merrill AH. Ceramide Synthase. Methods Enzymol 1999; 311:15‑21.
 23. Xu Z, Zhou J, McCoy DM et al. LASS5 is the predominant ceramide synthase isoform involved in de 
novo sphingolipid synthesis in lung epithelia. J Lipid Res 2005; 46:1229‑1238.
 24. Mandon EC, Ehses I, Rother J et al. Subcellular localization and membrane topology of serine palmi‑
toyltransferase, 3‑dehydrosphinganine reductase and sphinganine N‑acyltransferase in mouse liver. J Biol 
Chem 1992; 267:11144‑11148.
 25. Hirschberg K, Rodger J, Futerman AH. he long‑chain sphingoid base of sphingolipids is acylated at the 
cytosolic surface of the endoplasmic reticulum in rat liver. Biochem J 1993; 290:751‑757.
 26. Bionda C, Portoukalian J, Schmitt D et al. Subcellular compartmentalization of ceramide metabolism: 
MAM (mitochondria‑associated membrane) and/or mitochondria? Biochem J 2004; 382:527‑533.
 27. Yu J, Novgorodov SA, Chudakova D et al. JNK3 signaling pathway activates ceramide synthase leading 
to mitochondrial dysfunction. J Biol Chem 2007; 282:25940‑25949.
 28. Wang E, Norred WP, Bacon CW et al. Inhibition of sphingolipid biosynthesis by fumonisins. Implications 
for diseases associated with Fusarium moniliforme. J Biol Chem 1991; 266:14486‑14490.
 29. Merrill AH Jr, van Echten G, Wang E et al. Fumonisin B1 inhibits sphingosine (sphinganine) 
N‑acyltransferase and de novo sphingolipid biosynthesis in cultured neurons in situ. J Biol Chem 1993; 
268:27299‑27306.
 30. Yoo HS, Norred WP, Wang E et al. Fumonisin inhibition of de novo sphingolipid biosynthesis and cyto‑
toxicity are correlated in LLC‑PK1 cells. Toxicol Appl Pharmacol 1992; 114:9‑15.
 31. Wu WI, McDonough VM, Nickels JT et al. Regulation of lipid biosynthesis in Saccharomyces cerevisiae 
by fumonisin B1. J Biol Chem 1995; 270:13171‑13178.
 32. Harel R, Futerman AH. Inhibition of sphingolipid synthesis afects axonal outgrowth in cultured hip‑
pocampal neurons. J Biol Chem 1993; 268:14476‑14481.
 33. Schwarz A, Futerman AH. Inhibition of sphingolipid synthesis, but not degradation, alters the rate of 
dendrite growth in cultured hippocampal neurons. Brain Res Dev Brain Res 1998; 108:125‑130.
 34. Mandala SM, hornton RA, Frommer BR et al. he discovery of australifungin, a novel inhibitor of 
sphinganine N‑acyltransferase from Sporormiella australis. Producing organism, fermentation, isolation 
and biological activity. J Antibiot (Tokyo) 1995; 48:349‑356.
 35. Kobayashi SD, Nagiec MM. Ceramide/long‑chain base phosphate rheostat in Saccharomyces cerevisiae: 
regulation of ceramide synthesis by Elo3p and Cka2p. Eukaryot Cell 2003; 2:284‑294.
 36. Lahiri S, Park H, Laviad EL et al. Ceramide synthesis is modulated by the sphingosine analog FTY720 
via a mixture of uncompetitive and non‑competitive inhibition in an acyl CoA chain length‑dependent 
manner. J Biol Chem 2009; 284:16090‑16098.
 37. Bose R, Verheij M, Haimovitz‑Friedman A et al. Ceramide synthase mediates daunorubicin‑induced 
apoptosis: an alternative mechanism for generating death signals. Cell 1995; 82:405‑414.
 38. Yano M, Kishida E, Muneyuki Y et al. Quantitative analysis of ceramide molecular species by high per‑
formance liquid chromatography. J Lipid Res 1998; 39:2091‑2098.
 39. Becker KP, Kitatani K, Idkowiak‑Baldys J et al. Selective inhibition of juxtanuclear translocation of protein 
kinase C betaII by a negative feedback mechanism involving ceramide formed from the salvage pathway. 
J Biol Chem 2005; 280:2606‑2612.
 40. Kitatani K, Idkowiak‑Baldys J, Bielawski J et al. Protein kinase C‑induced activation of a ceramide/protein phos‑
phatase 1 pathway leading to dephosphorylation of p38 MAPK. J Biol Chem 2006; 281:36793‑36802.
 41. Aronova S, Wedaman K, Aronov PA et al. Regulation of ceramide biosynthesis by TOR complex 2. Cell 
Metab 2008; 7:148‑158.
 42. Mulet JM, Martin DE, Loewith R et al. Mutual antagonism of target of rapamycin and calcineurin signal‑
ing. J Biol Chem 2006; 281:33000‑33007.
 43. Tabuchi M, Audhya A, Parsons AB et al. he phosphatidylinositol 4,5‑biphosphate and TORC2 binding 
proteins Slm1 and Slm2 function in sphingolipid regulation. Mol Cell Biol 2006; 26:5861‑5875.
 44. Wang YL, Wang Y, Tong L et al. Overexpression of calcineurin B subunit (CnB) enhances the oncogenic 
potential of HEK293 cells. Cancer Sci 2008; 99:1100‑1108.
©
20
09
 C
op
yr
ig
ht
 L
an
de
s B
io
sc
ie
nc
e.
 N
ot
 fo
r 
D
is
tr
ib
ut
io
n
11Ceramide Synthesis and Cell Signaling
 45. Villen J, Beausoleil SA, Gerber SA et al. Large‑scale phosphorylation analysis of mouse liver. Proc Natl 
Acad Sci USA 2007; 104:1488‑1493.
 46. Min J, Mesika A, Sivaguru M et al. (Dihydro)ceramide synthase 1 regulated sensitivity to cisplatin is 
associated with the activation of p38 mitogen‑activated protein kinase and is abrogated by sphingosine 
kinase 1. Mol Cancer Res 2007; 5:801‑812.
 47. Sridevi P, Alexander H, Laviad EL et al. Ceramide synthase 1 is regulated by proteasomal mediated turnover. 
Biochim Biophys Acta 2009; 1793:1218‑1227.
 48. Kageyama‑Yahara N, Riezman H. Transmembrane topology of ceramide synthase in yeast. Biochem J 2006; 
398:585‑593.
 49. Rost B. PHD: predicting one‑dimensional protein structure by proile‑based neural networks. Methods 
Enzymol 1996; 266:525‑539.
 50. Sot J, Aranda FJ, Collado MI et al. Diferent efects of long‑ and short‑chain ceramides on the gel‑luid 
and lamellar‑hexagonal transitions of phospholipids: a calorimetric, NMR and x‑ray difraction study. 
Biophys J 2005; 88:3368‑3380.
 51. Pinto SN, Silva LC, de Almeida RF et al. Membrane domain formation, interdigitation and morphological 
alterations induced by the very long chain asymmetric C24:1 ceramide. Biophys J 2008; 95:2867‑2879.
 52. Kroesen BJ, Jacobs S, Pettus BJ et al. BcR‑induced apoptosis involves diferential regulation of C16 and 
C24‑ceramide formation and sphingolipid‑dependent activation of the proteasome. J Biol Chem 2003; 
278:14723‑14731.
 53. Koybasi S, Senkal CE, Sundararaj K et al. Defects in cell growth regulation by C18:0‑ceramide and longevity as‑
surance gene 1 in human head and neck squamous cell carcinomas. J Biol Chem 2004; 279:44311‑44319.
 54. Senkal CE, Ponnusamy S, Rossi MJ et al. Role of human longevity assurance gene 1 and C18‑ceramide 
in chemotherapy‑induced cell death in human head and neck squamous cell carcinomas. Mol Cancer her 
2007; 6:712‑722.
 55. Karahatay S, homas K, Koybasi S et al. Clinical relevance of ceramide metabolism in the pathogenesis of 
human head and neck squamous cell carcinoma (HNSCC): attenuation of C(18)‑ceramide in HNSCC 
tumors correlates with lymphovascular invasion and nodal metastasis. Cancer Lett 2007; 256:101‑111.
 56. Baran Y, Salas A, Senkal CE et al. Alterations of ceramide/sphingosine 1‑phosphate rheostat involved in 
the regulation of resistance to imatinib‑induced apoptosis in K562 human chronic myeloid leukemia cells. 
J Biol Chem 2007; 282:10922‑10934.
 57. Becker I, Wang‑Eckhardt L, Yaghootfam A et al. Diferential expression of (dihydro)ceramide syn‑
thases in mouse brain: oligodendrocyte‑speciic expression of CerS2/Lass2. Histochem Cell Biol 2008; 
129:233‑241.
 58. Coderch L, Lopez O, de la Maza A et al. Ceramides and skin function. Am J Clin Dermatol 2003; 
4:107‑129.
 59. Rabionet M, van der Spoel AC, Chuang CC et al. Male germ cells require polyenoic sphingolipids with 
complex glycosylation for completion of meiosis: a link to ceramide synthase‑3. J Biol Chem 2008; 
283:13357‑13369.
 60. Pettus BJ, Baes M, Busman M et al. Mass spectrometric analysis of ceramide perturbations in brain and 
ibroblasts of mice and human patients with peroxisomal disorders. Rapid Commun Mass Spectrom 2004; 
18:1569‑1574.
 61. Eto M, Bennouna J, Hunter OC et al. C16 ceramide accumulates following androgen ablation in LNCaP 
prostate cancer cells. Prostate 2003; 57:66‑79.
 62. Osawa Y, Uchinami H, Bielawski J et al. Roles for C16‑ceramide and sphingosine 1‑phosphate in regulating 
hepatocyte apoptosis in response to tumor necrosis factor‑alpha. J Biol Chem 2005; 280:27879‑27887.
 63. Kolaczkowski M, Kolaczkowska A, Gaigg B et al. Diferential regulation of ceramide synthase components 
LAC1 and LAG1 in Saccharomyces cerevisiae. Eukaryot Cell 2004; 3:880‑892.
 64. Dickson RC. hematic review series: sphingolipids. New insights into sphingolipid metabolism and func‑
tion in budding yeast. J Lipid Res 2008; 49:909‑921.
 65. Bartke N, Hannun YA. Bioactive sphingolipids: metabolism and function. J Lipid Res 2008.
 66. Reynolds CP, Maurer BJ, Kolesnick RN. Ceramide synthesis and metabolism as a target for cancer therapy. 
Cancer Lett 2004; 206:169‑180.
 67. Dbaibo GS, Kfoury Y, Darwiche N et al. Arsenic trioxide induces accumulation of cytotoxic levels of 
ceramide in acute promyelocytic leukemia and adult T‑cell leukemia/lymphoma cells through de novo ce‑
ramide synthesis and inhibition of glucosylceramide synthase activity. Haematologica 2007; 92:753‑762.
 68. Jin J, Hou Q, Mullen TD et al. Ceramide generated by sphingomyelin hydrolysis and the salvage pathway 
is involved in hypoxia/reoxygenation‑induced Bax redistribution to mitochondria in NT‑2 cells. J Biol 
Chem 2008; 283:26509‑26517.
 69. Panjarian S, Kozhaya L, Arayssi S et al. De novo N‑palmitoylsphingosine synthesis is the major biochemical 
mechanism of ceramide accumulation following p53 up‑regulation. Prostaglandins Other Lipid Mediat 
2008; 86:41‑48.
©
20
09
 C
op
yr
ig
ht
 L
an
de
s B
io
sc
ie
nc
e.
 N
ot
 fo
r 
D
is
tr
ib
ut
io
n
12 Sphingolipids as Signaling and Regulatory Molecules
 70. Pandey S, Murphy RF, Agrawal DK. Recent advances in the immunobiology of ceramide. Exp Mol Pathol 
2007; 82:298‑309.
 71. Lahiri S, Futerman AH. he metabolism and function of sphingolipids and glycosphingolipids. Cell Mol 
Life Sci 2007; 64:2270‑2284.
 72. Summers SA. Ceramides in insulin resistance and lipotoxicity. Prog Lipid Res 2006; 45:42‑72.
 73. Ito Y, Sato S, Ohashi T et al. Reduction of airway anion secretion via CFTR in sphingomyelin pathway. 
Biochem Biophys Res Commun 2004; 324:901‑908.
 74. Vilela RM, Lands LC, Meehan B et al. Inhibition of IL‑8 release from CFTR‑deicient lung epithelial 
cells following pretreatment with fenretinide. Int Immunopharmacol 2006; 6:1651‑1664.
 75. Petrache I, Natarajan V, Zhen L et al. Ceramide upregulation causes pulmonary cell apoptosis and 
emphysema‑like disease in mice. Nat Med 2005; 11:491‑498.
 76. Petrache I, Natarajan V, Zhen L et al. Ceramide causes pulmonary cell apoptosis and emphysema: a role 
for sphingolipid homeostasis in the maintenance of alveolar cells. Proc Am horac Soc 2006; 3:510.
 77. Morales A, Lee H, Goni FM et al. Sphingolipids and cell death. Apoptosis 2007; 12:923‑939.
 78. Llacuna L, Mari M, Garcia‑Ruiz C et al. Critical role of acidic sphingomyelinase in murine hepatic 
ischemia‑reperfusion injury. Hepatology 2006; 44:561‑572.
 79. Mari M, Caballero F, Colell A et al. Mitochondrial free cholesterol loading sensitizes to TNF‑ and 
Fas‑mediated steatohepatitis. Cell Metab 2006; 4:185‑198.
 80. Lang PA, Schenck M, Nicolay JP et al. Liver cell death and anemia in Wilson disease involve acid sphin‑
gomyelinase and ceramide. Nat Med 2007; 13:164‑170.
 81. Cutler RG, Kelly J, Storie K et al. Involvement of oxidative stress‑induced abnormalities in ceramide 
and cholesterol metabolism in brain aging and Alzheimer’s disease. Proc Natl Acad Sci USA 2004; 
101:2070‑2075.
 82. Wang G, Silva J, Dasgupta S et al. Long‑chain ceramide is elevated in presenilin 1 (PS1M146V) mouse 
brain and induces apoptosis in PS1 astrocytes. Glia 2008; 56:449‑456.
 83. Schwarz A, Futerman AH. Distinct roles for ceramide and glucosylceramide at diferent stages of neuronal 
growth. J Neurosci 1997; 17:2929‑2938.
 84. Lee JT, Xu J, Lee JM et al. Amyloid‑beta peptide induces oligodendrocyte death by activating the neutral 
sphingomyelinase‑ceramide pathway. J Cell Biol 2004; 164:123‑131.
 85. Jana A, Pahan K. Fibrillar amyloid‑beta peptides kill human primary neurons via NADPH oxidase‑mediated 
activation of neutral sphingomyelinase. Implications for Alzheimer’s disease. J Biol Chem 2004; 
279:51451‑51459.
 86. Yu ZF, Nikolova‑Karakashian M, Zhou D et al. Pivotal role for acidic sphingomyelinase in cerebral isch‑
emia‑induced ceramide and cytokine production and neuronal apoptosis. J Mol Neurosci 2000; 15:85‑97.
 87. Uchida Y, Nardo AD, Collins V et al. De novo ceramide synthesis participates in the ultraviolet B 
irradiation‑induced apoptosis in undiferentiated cultured human keratinocytes. J Invest Dermatol 2003; 
120:662‑669.
 88. Jenkins GM, Richards A, Wahl T et al. Involvement of yeast sphingolipids in the heat stress response of 
Saccharomyces cerevisiae. J Biol Chem 1997; 272:32566‑32572.
 89. Wells GB, Dickson RC, Lester RL. Heat‑induced elevation of ceramide in Saccharomyces cerevisiae via 
de novo synthesis. J Biol Chem 1998; 273:7235‑7243.
 90. Jenkins GM, Cowart LA, Signorelli P et al. Acute activation of de novo sphingolipid biosynthesis upon 
heat shock causes an accumulation of ceramide and subsequent dephosphorylation of SR proteins. J Biol 
Chem 2002; 277:42572‑42578.
 91. Perry DK, Carton J, Shah AK et al. Serine palmitoyltransferase regulates de novo ceramide generation 
during etoposide‑induced apoptosis. J Biol Chem 2000; 275:9078‑9084.
 92. Basnakian AG, Ueda N, Hong X et al. Ceramide synthase is essential for endonuclease‑mediated death 
of renal tubular epithelial cells induced by hypoxia‑reoxygenation. Am J Physiol Renal Physiol 2005; 
288:F308‑314.
 93. Cuzzocrea S, Di Paola R, Genovese T et al. Anti‑inlammatory and anti‑apoptotic efects of fumonisin 
B1, an inhibitor of ceramide synthase, in a rodent model of splanchnic ischemia and reperfusion injury. J 
Pharmacol Exp her 2008; 327:45‑57.
 94. Meyer SG, de Groot H. Cycloserine and threo‑dihydrosphingosine inhibit TNF‑alpha‑induced cytotoxic‑
ity: evidence for the importance of de novo ceramide synthesis in TNF‑alpha signaling. Biochim Biophys 
Acta 2003; 1643:1‑4.
 95. Veluthakal R, Jangati GR, Kowluru A. IL‑1beta‑induced iNOS expression, NO release and loss in metabolic 
cell viability are resistant to inhibitors of ceramide synthase and sphingomyelinase in INS 832/13 cells. 
Jop 2006; 7:593‑601.
 96. Turnbull KJ, Brown BL, Dobson PR. Caspase‑3‑like activity is necessary but not sufficient for 
daunorubicin‑induced apoptosis in Jurkat human lymphoblastic leukemia cells. Leukemia 1999; 
13:1056‑1061.
©
20
09
 C
op
yr
ig
ht
 L
an
de
s B
io
sc
ie
nc
e.
 N
ot
 fo
r 
D
is
tr
ib
ut
io
n
